PTJ
UROV

Paul Tudor Jones’s Urovant Sciences Ltd. UROV Stock Holding History

Paul Tudor Jones’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$120K – 1309
2018
Q3 		$120K Buy
+10,000
New +$118K ﹤0.01% 1012

Other funds holding UROV

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Paul Tudor Jones's UROV Position: Q4 2018 in Review

Paul Tudor Jones sold out of Urovant Sciences Ltd. (UROV) in Q4 2018, closing a stake of 10,000 shares — an estimated $120K sold.

Paul Tudor Jones first reported a position in UROV in Q3 2018 and held it in 1 quarter. The position peaked at $120K in Q3 2018. 26 funds tracked by Wall St. Rank hold UROV as of Q4 2018.

  • Paul Tudor Jones reported no remaining Urovant Sciences Ltd. position as of Q4 2018 after selling out during the quarter.
  • Paul Tudor Jones sold 10,000 Urovant Sciences Ltd. shares in Q4 2018, an estimated $120K.
  • Paul Tudor Jones first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 1 quarter.
  • Paul Tudor Jones's Urovant Sciences Ltd. position peaked at $120K in Q3 2018.
  • 26 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2018.

Based on Tudor Investment Corp's 13F filing for Q4 2018, filed 14 Feb 2019.